Search Results

The Randox Laboratories Limited Haemoglobin Are Test Kit is an in vitro diagnostic reagent for the quantitative determination of haemoglobin Ay, (HbAz) in whole blood. The method is an immunological assay. Both the concentration of HbAr, and the concentration of total haemoglobin are measured. The reported HbAzz result is calculated as a percentage of the total haemoglobin concentration.

Measurements of percentage HbAy, are effective in monitoring long-term glucose control in individuals with diabetes mellitus.

This application sheet has been developed for the Hitachi 717 clinical chemistry analyser and must be used by suitably qualified laboratory personnel under appropriate clinical laboratory conditions.

The Randox Laboratories Limited Haemoglobin Are Test Kit is an in vitro diagnostic reagent for the quantitative determination of haemoglobin Ay, (HbAz) in whole blood. The method is an immunological assay. Both the concentration of HbAr, and the concentration of total haemoglobin are measured. The reported HbAzz result is calculated as a percentage of the total haemoglobin concentration.

The provided document is a 510(k) premarket notification letter from the FDA for a device named "HAEMOGLOBIN Asc" (also referred to as "HAEMOGLOBIN A1c"). This letter primarily addresses the substantial equivalence determination for the device. Clinical studies information, including acceptance criteria and detailed study data, is typically found in the 510(k) summary or other supporting documents submitted by the manufacturer, which are not present in the provided excerpts.

Therefore, most of the requested information regarding acceptance criteria, study details, sample sizes, expert qualifications, and ground truth types cannot be extracted from the given text.

However, based on the document, I can provide the following:

1. A table of acceptance criteria and the reported device performance:

This information is not provided in the given FDA letter or the "Indications For Use" statement. The letter primarily confirms the substantial equivalence of the device to a predicate and does not detail performance characteristics or acceptance criteria.

2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective):

This information is not provided in the given text.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience):

This information is not provided in the given text.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

This information is not provided in the given text.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

This device is an "in vitro diagnostic reagent for the quantitative determination of haemoglobin A1c." It is a laboratory assay, not an AI-assisted diagnostic imaging device or one that involves human "readers" in the context of MRMC studies. Therefore, an MRMC study and related effect sizes are not applicable to this type of device.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

The device is described as an "immunological assay" and an "in vitro diagnostic reagent." As such, its performance is typically evaluated as a standalone analytical device, measuring a biomarker. It's not an algorithm in the sense of AI software, though it's designed to perform its function without human interpretation of raw data beyond reading the final result. Therefore, a "standalone" performance evaluation in the context of analytical accuracy and precision would have been conducted, but specific details are not provided.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc):

For a glycosylated hemoglobin assay, the "ground truth" for assessing its performance would typically involve comparison against a reference method or a gold standard method for measuring HbA1c, along with samples characterized by known HbA1c levels or clinical diagnoses of diabetes. Details on the specific ground truth used are not provided in the given document.

8. The sample size for the training set:

This information is not provided in the given text. (Note: For an in vitro diagnostic assay, the concept of a "training set" as understood in machine learning might not directly apply. Instead, there would be validation studies using numerous samples.)

9. How the ground truth for the training set was established:

This information is not provided in the given text, and the concept of a "training set" ground truth is less directly applicable for this type of device as explained above.

Ask a specific question about this device